Piramal Pharma share news and announcements
NSE: PPLPHARMABSE: 543635Pharmaceuticals & BiotechnologySmall Cap
Last close ₹191.07down ₹3.92 (2.01%)BSE ₹190.85
Share price at the NSE close on 23 Oct 2026. Previous close ₹194.99.
52-week range of traded prices to 23 Oct 2026
₹132.30Low, 23 Mar 2026₹231.93High, 8 Sep 2026
- Next results date: the board meets on 27 Oct 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹25,438 Cr331st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 28 Apr 2026
- 3.1
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 29 Jul 2026
- −3.9%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹217 crore of one-off items, the largest of them in the quarter to Mar 2026.
- −1.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 29 Jul 2026
- 1.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 28 Apr 2026
- 0.67
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 24,65,51342.5% delivered
Piramal Pharma share news and announcements
317 announcements, routine notices left out, newest first. Page 4 of 7.
Jan 2025
Dec 2024
Nov 2024
8 Nov · Giving guarantees/indemnity/ becoming a surety for third party
8 Nov · Legal
Exchange has sought clarification from Piramal Pharma Limited for the quarter ended 30-Sep-2024 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results not submitted as per Indian Accounting Standard. The response of the Company is awaited.
Oct 2024
29 Oct · Analysts
23 Oct · Board meeting
22 Oct · Rating
21 Oct · Legal
14 Oct · Analysts
8 Oct · Management
Sep 2024
18 Sep · Analysts
Aug 2024
30 Aug · Business
23 Aug · Analysts
5 Aug · Analysts
1 Aug · Rating
Jul 2024
26 Jul · Board meeting
26 Jul · Board meeting
26 Jul · Disclosure
23 Jul · Business
15 Jul · Analysts
2 Jul · Meeting
Jun 2024
11 Jun · Corporate action
4 Jun · Analysts
May 2024
28 May · Disclosure
17 May · Analysts
10 May · Management